Amended agreement reflects growing excitement in the field for targeting intracellular Tau and significant progress made with our Morphomer small molecules
Investigational New Drug (IND)-enabling studies to commence in H1 2026
Lausanne, Switzerland, April 7, 2026 -- AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced an agreement with Eli Lilly and Company (Lilly) to amend their 2018 license and collaboration agreement to research and develop Tau aggregation inhibitor small molecules for the potential treatment of Alzheimer's disease (AD) and other neurodegenerative diseases. The amendment continues the research and collaboration to cover development of new lead Tau Morphomer® candidates and potential back-up compounds.
Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: "The progress in this collaboration highlights the important breakthroughs we have made with Morphomer small molecules for intracellular targeting of Tau. We look forward to working with the team at Lilly to drive forward the development of these potentially disruptive small molecule therapeutics for early-stage treatment and long-term prevention of neurodegenerative diseases. Increasingly, the scientific evidence suggests that targeting intracellular Tau can slow or even completely halt the pathology. This collaboration exemplifies our work towards precision prevention of neurodegenerative diseases. We expect to initiate Investigational New Drug (IND)-enabling studies imminently."
Morphomer Tau candidates were selected for their ability to enter the brain when dosed orally, and for their specific binding to the targeted pathological ...
